Abstract
AbstractThe purpose of this study is to conduct a comparative analysis of the impact of the accessibility and quality of medical care provided to patients with chronic noncommunicable diseases (CNCDs) during COVID-19 pandemic on the course and outcome of COVID-19 infection. The study included 132 patients hospitalized with a diagnosis of COVID-19 and having one or more concomitant CNCDs. The patients were divided into two groups based on the quality of the initial CNCD therapy they received. Group 1 involved 58 patients (42%) who received treatment according to clinical guidelines and had a compensated CNCD. Group 2 consisted of 76 patients (58%) who received treatment that was not in line with modern clinical guidelines and/or had a decompensated CNCD. All ‘red zone’ hospitalized patients were surveyed. In particular, they were asked questions related to the quality and accessibility of medical care during COVID-19 pandemic and their satisfaction with the medical care received during the pandemic. Reduced access to medical care (the failure to have the therapy received timely evaluated and adjusted) during COVID-19 pandemic affects the quality of the therapy received by patients with CNCDs. Generally, an unfavorable course and outcome of COVID-19 infection are typical for patients receiving a non-optimal CNCD therapy as compared to patients receiving a therapy that meets current clinical guidelines.
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Pulmonary and Respiratory Medicine
Reference26 articles.
1. World Health Organization. NCDs. Geneva; 2018.
2. Arutyunov, G. P. et al. International register “Dynamics analysis of comorbidities in SARS-CoV-2 survivors” (AKTIV SARS-CoV-2): analysis of predictors of short-term adverse outcomes in COVID-19. Rus. J. Cardiol. 26, 116–131 (2021).
3. Pinto-Sietsma, S. J. et al. Antihypertensive drugs in COVID-19 infection. Eur. Heart J. Cardiovasc. Pharmacother. 6, 415–416 (2020).
4. Lopes, R. D. et al. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA 325, 254–264 (2021).
5. Cohen, J. B. et al. Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admited to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir. Med. 9, 275–284 (2021).
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献